Persons with a History of Myocarditis or Pericarditis
Myocarditis or pericarditis after a dose of COVID-19 vaccine:
- Development of myocarditis or pericarditis after a dose COVID-19 vaccine is a precaution to a subsequent dose of any COVID-19 vaccine and subsequent doses should generally be avoided.
- If, after a risk assessment, the decision is made to administer a subsequent COVID-19 vaccine dose, the person should wait until at least after their episode of myocarditis or pericarditis has resolved
- For people ages 18 years and older who choose to receive a subsequent COVID-19 vaccine, some experts advise the use of Janssen COVID-19 Vaccine be considered. These people should be aware of the risk of TTS.
History of myocarditis or pericarditis prior/unrelated to COVID-19 vaccination:
- May receive any FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved
Page last reviewed: August 17, 2022